KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Accounts Payables (2016 - 2026)

NovoCure's Accounts Payables history spans 13 years, with the latest figure at $127.2 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 33.81% to $127.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $127.2 million, a 33.81% increase, with the full-year FY2025 number at $122.2 million, up 16.32% from a year prior.
  • Accounts Payables hit $127.2 million in Q1 2026 for NovoCure, up from $122.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for NVCR hit a ceiling of $127.2 million in Q1 2026 and a floor of $69.2 million in Q1 2022.
  • Historically, Accounts Payables has averaged $93.4 million across 5 years, with a median of $90.2 million in 2024.
  • Biggest five-year swings in Accounts Payables: skyrocketed 40.72% in 2022 and later rose 3.29% in 2023.
  • Tracing NVCR's Accounts Payables over 5 years: stood at $85.2 million in 2022, then grew by 10.79% to $94.4 million in 2023, then rose by 11.33% to $105.1 million in 2024, then rose by 16.32% to $122.2 million in 2025, then increased by 4.1% to $127.2 million in 2026.
  • Business Quant data shows Accounts Payables for NVCR at $127.2 million in Q1 2026, $122.2 million in Q4 2025, and $118.9 million in Q3 2025.